Genome & Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Genome & Company
Korean Bioventure Financing Continues Downward Spiral In Q3
VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.
A Closer Look At The Korean Microbiome Therapeutic Landscape
Scrip takes an infographic look at various factors to keep an eye on in South Korea's rapidly developing microbiome therapy landscape this year, including emerging companies and their pipelines.
Finance Watch: Mega-Rounds Add Up To Another Record Year For Biopharma VC Funding
Private Company Edition: NVCA and Pitchbook data show pharma and biotech companies raised $37.8bn in venture capital in 2021, up 41% from the record $26.8bn total in 2020. Recent mega-rounds include $190m for Maze and $200m for Alumis, and Sound Bioventures raised a €110m fund.
Korea Policies To Shift To Non-COVID Areas In 2022?
The Pink Sheet takes a look back at major policy developments in South Korea in 2021 and ahead at what’s in store for the coming year.
- Large Molecule
Drug Discovery Tools
- Natural Products
- Molecular Diversity
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.